{"name":"Eccogene","slug":"eccogene","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"ECC0509","genericName":"ECC0509","slug":"ecc0509","indication":"Other","status":"phase_2"}]},{"name":"Metabolic","slug":"metabolic","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"ECC4703","genericName":"ECC4703","slug":"ecc4703","indication":"Type 2 diabetes","status":"phase_2"}]}],"pipeline":[{"name":"ECC0509","genericName":"ECC0509","slug":"ecc0509","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ECC4703","genericName":"ECC4703","slug":"ecc4703","phase":"phase_2","mechanism":"ECC4703 is a small molecule targeting the SGLT2 receptor.","indications":["Type 2 diabetes"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMixAJBVV95cUxOTWRKUFFxSkZqdnVqMGlXaEVwaWtLV0dJc21RU2tqeGZpSzhhbEplcWFNUG8zVlk4OE9UVW56VmY0NmJkYjJTTTE0M3oxNlhteE1pNk1IQXhzZzVmTTZYNkVFR2tXMmlDdl84c1c5RHBSQU4wTDFhNzlCVDY5SldIcTBreHg0NnlRR0E0Q0hNM2xMRU43bXMwS0lkbGRKSzhHY2pWVkw2T29zd2w5TEItSW1uQjE5ejVOcmdZNWRQOTZfeFZyUEZucG9jZlZUMk9DMkhacVVPVngyU19ia04tUV9KZTZjM2duUldRN1Yzb2NraTB3VW5mbm9odEpJSEZxS2NvOWlZLThzaTRaWF9uZE9IRmVXd0d2YXVmRUhIOEtIaVItOVJzSGF6M0hDY3dENVhDODQzMzZ6U1BkWWlOdDM5Q2U?oc=5","date":"2026-04-08","type":"pipeline","source":"Barchart","summary":"Diabetes Market: Rapid Increment Driven by Innovation by 2032 – DelveInsight | Eli Lilly and Company, Regor Pharma AstraZeneca, Eccogene, Pfizer, Sciwind Biosciences USA Co., Ltd., MediciNova - Barcha","headline":"Diabetes Market: Rapid Increment Driven by Innovation by 2032 – DelveInsight | Eli Lilly and Company, Regor Pharma Astra","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijAFBVV95cUxObFV4alhocjNxdjJUcHItOE4zT1g0a0dCcmFPMFdMazV2T1JlWG9FUEE5SEV6OExZRUt5QVQtNllBenNFQ19NdHM4ZXFPWjJqWFlpZW9rWC1rUWJQbDVsOHNNQVMzYkZJNm9Td3g4eklGM1hOaGZhVnNaSG1IUnBMSEt4Njc1SUI3aW5RZg?oc=5","date":"2025-12-18","type":"pipeline","source":"thebambooworks.com","summary":"Lagging in the weight-loss market? Take Fosun’s GLP-1 pill - thebambooworks.com","headline":"Lagging in the weight-loss market? Take Fosun’s GLP-1 pill","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi1AFBVV95cUxNTUM0WHB0Vk9TWTRqZTdrM0s4Q3dNN2ZjVkZQdk1kM3VwdEdaMHNGVndOR3lCT2pxVVhEbkNjNS1ydWZ6TUlQdVFYSGkyUE9qbGktTW5aZWRodUxNMVc4anZHWUpxZHR2MVhfbHFBbWUxMW0tN2V2RUw5ZUJXOUVJOC1SNHVfeC1BekRBNEM5bGkxODJJbHRHX3g2dTd3Mm85aWZfY2dyeVlpbnVjSXNHUkNHa1RyRElSYm9FdHROSllWQWxTck9aNkZXemo0N0UzQlFPMA?oc=5","date":"2025-10-23","type":"deal","source":"Sahm","summary":"Eccogene Eyes Hong Kong IPO With Experimental Weight-Loss Drug, AstraZeneca Partnership - Sahm","headline":"Eccogene Eyes Hong Kong IPO With Experimental Weight-Loss Drug, AstraZeneca Partnership","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimgFBVV95cUxNbjI1NnNFUWJEeTBHSGpaVWVCc3l6SG9VaUxVcURUY1FFa2VILW9pMW1KOFdRYjNDZjZ5WXh4TTh4ZGtvQWFneks2bGZjOVdnM281N19sOE5JSXF5TVRDNl81VmF6VU9HNGlMT3lMSE1vWGUwc2ItUkc1bS1fc2FVcXRzZmJtS1NZTXliUTBvYTY1Nmh4SjlhZ2xn?oc=5","date":"2025-10-08","type":"trial","source":"Endpoints News","summary":"Eccogene files for Hong Kong IPO to back development of GLP-1 pipeline - Endpoints News","headline":"Eccogene files for Hong Kong IPO to back development of GLP-1 pipeline","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilwFBVV95cUxQRHlZOVdsSXlTMFZwS19zdkpfcnQ3b3htTVBOVmJhR1pTeG9pR2w2U1VLVDBxaEpRSEg0R3hvTEFaVGI4NDh6LTNrNU14d29Bb0ViTFNXZXNMS09yQkJqQndvRThCckp6Y0hfM0lkRlk5VjRqM0xXQ0d5ZHZQeE56WEUtNmpDckQtd0o4ZzFybjRJdGx5SkZN?oc=5","date":"2024-10-24","type":"pipeline","source":"The Pharma Letter","summary":"$60 million AstraZeneca milestone payment for Eccogene - The Pharma Letter","headline":"$60 million AstraZeneca milestone payment for Eccogene","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitwFBVV95cUxPaU5nVkk4Sm5qTzBINm9WQk9qbFp2QVdNVVFXOHdlWkQwR2JwcmY5ZmR5M3dtUjQxTU8zVzk2bGg0ckVyU3pPSXJIRDVMTUNzOGJMOENlTDZXUy0waFJaWVZpSmRkLTNVVmY1cXQ5a0JBcXJYcGc4REZHaGxSbld1WENMR3FVMUZfQ3BSSkRfV1hyb2Zna0JMbjRCNjg3WmE1ZjRkUjFsMXgtdnBUZkNnbU5KX0VyemM?oc=5","date":"2023-11-09","type":"deal","source":"AstraZeneca","summary":"AstraZeneca licenses novel agent for the treatment of cardiometabolic conditions and obesity - AstraZeneca","headline":"AstraZeneca licenses novel agent for the treatment of cardiometabolic conditions and obesity","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitgFBVV95cUxOeml1RXV6emg1OHRxeVd4cVdLYmVWWmtnVEg4cngtUmE4RnZJdVV3MU13RTFWMWZpdE9DSFBrNWV5TWh1WEJWVW9JdmdybFdibXNLV1UxYnlOem5RT2piaTNwaDVDN191MzVtamhHR0ZsOXBqWEtHT0d6cU13TXNHbDMtRzNuSXVydC1Na3VVRFRveUNaeUhaaFFSdE5fdHFNakpiOWVveVNkWElPZTN0MGVzTWw3QQ?oc=5","date":"2023-11-09","type":"deal","source":"Contract Pharma","summary":"AstraZeneca, Eccogene Enter Exclusive License Agreement for GLP-1 Drug - Contract Pharma","headline":"AstraZeneca, Eccogene Enter Exclusive License Agreement for GLP-1 Drug","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirAFBVV95cUxORUFXbjNpWU02TzBQeW9laXBUbnF5SFlMdVVpbnVuVjZ0b3FodVRJc2dMaEd3Q1o0QlZzNGU1WGlRZ1B5TkE4MHZMUm5nY0ItMGU2MFlzU1RZZl9VQmtVX2hiSlBOZjh5WUpmS2lUWl9BaExOc0VnWGdTcFVfdEY0QkphUDhVRkZoQy1idWF5VGRnc0FLVzg0LVo2bzlzV3U2ZXJ5Mng5bTQ4V1JV?oc=5","date":"2023-11-09","type":"deal","source":"Pharmaceutical Technology","summary":"AstraZeneca targets obesity market with Eccogene partnership - Pharmaceutical Technology","headline":"AstraZeneca targets obesity market with Eccogene partnership","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMif0FVX3lxTFBIMjRqeFFVU1E1TC16TE4xN0ZkRDY1VUxIREwzUmZOX1lMRTdTQ3hSSnRHb3VaZ3lsVkRuQUVEeEUwVTZNTHJ5cFJlUmVCR1FjMnRWbHdNRUxBT0k1UURpWnlwZVhqcGduVE44MlU0cEg4Ylk2cWt4eEFsbHdIN2c?oc=5","date":"2023-11-09","type":"deal","source":"pharmaphorum","summary":"AstraZeneca builds in obesity with $2bn+ Eccogene deal - pharmaphorum","headline":"AstraZeneca builds in obesity with $2bn+ Eccogene deal","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixgFBVV95cUxORjd3dF9SdHk2MENpUmFXM3VkZW5vR2VZS0lHc01vM3dfenNoLTlCUU0wcEt4b3RiVHpHTmk2Q1pRYmVkNVdFQzViNnNHYkpRYkkyWVNtbVpNN2gzcTlwNHhFTnQzNGc0YXNhVnExTlo4SDhzSTRkcWN3bHU1ellxMklibEhITEV0eXVPX0NTS29VNXRiQnN1TVR5VnBZX2o1d0E3cjZNcDFDQlhfX0JzQ0FfVWRpZWptRVpRRHlieDdFMXJMOUE?oc=5","date":"2023-11-09","type":"trial","source":"Fierce Biotech","summary":"AstraZeneca pays $185M upfront to reenter oral obesity gold rush, drops phase 2 sickle cell drug - Fierce Biotech","headline":"AstraZeneca pays $185M upfront to reenter oral obesity gold rush, drops phase 2 sickle cell drug","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMizwFBVV95cUxOVEdkakJQc25NOC10TXQ0RlpLN09TTW5pc2VmVGhsLWRrZllTbzR2Q280WkZBQ3pGV3lkX29VUzlYVWFDVWllTkgxMjc3eEg4bUJrXzJNZmNleFY4a3QzYkxHS09HNDBRZGZ6dDhDdms5SFh0VXhYcXNXTUZNdVhhVXVXQ19BbWtrM1cxYU9NMFRfdFNVQng0TG10QS05dVR0QjE5Z0YxNlRFOHJJd2plVi1ZMjVqcjFVVkNZMzBPT0ZVOE5lekVlanJRNlhMRHM?oc=5","date":"2023-11-09","type":"deal","source":"Reuters","summary":"AstraZeneca raises stakes in obesity drug race with Eccogene deal - Reuters","headline":"AstraZeneca raises stakes in obesity drug race with Eccogene deal","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirAFBVV95cUxPcGlmOGc5S1h6ZUZxYktxMktlOUhoQy1Vb19SZ2F3Rk9Lak9PaV9SVE5hVGRZdUUzaUwxYmFBanJZSkRQTHNwVVYxU1F4WF9WSG5Jai1lUEh3SDJBdzZWMDNFa19JSzVkdXAtYnlEWnJYNEpzeE1lQkg5MEd3a2hnc3pZQS00SGF3d2FWZnVVRnQwSTduZTJ2OUN4NHp3UWNYYktUTjAtZGhXNm9T?oc=5","date":"2023-11-09","type":"deal","source":"BioSpace","summary":"AstraZeneca Targets Obesity Market with Potential $2B Deal for Early GLP-1 Candidate - BioSpace","headline":"AstraZeneca Targets Obesity Market with Potential $2B Deal for Early GLP-1 Candidate","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"phase_2":2},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}